A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Study ID
- NCT01185288
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Adalimumab — BIOLOGICALAdalimumab in pre-filled syringes
- Methotrexate — DRUGMethotrexate capsule
Study Details
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis (RA).
Key Dates
- Start date
- Sep 30, 2010
- Status verified
- Jan 2014
- Primary completion
- Jan 31, 2013
- Completion
- Jan 31, 2013
Study Design
- Enrollment
- 309 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Adalimumab + Low Dose MethotrexateOpen-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
- Active Comparator: Adalimumab + High Dose MethotrexateOpen-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
Primary Outcome Measure
Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24 [ Time Frame: Week 24 ]
Locations (46)
Find similar trials in Huntsville, AL
By condition
By research site
Site Reference ID/Investigator# 38982· Huntsville, ALSite Reference ID/Investigator# 38686· Tuscaloosa, ALSite Reference ID/Investigator# 42044· Mesa, AZSite Reference ID/Investigator# 37983· Phoenix, AZSite Reference ID/Investigator# 44823· Little Rock, ARSite Reference ID/Investigator# 37981· Hemet, CA
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama